articleTop 1% cited

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Leukemia · 2012 · Vol. 26(9) · pp. 2096–2102

Benjamin Hanfstein✉(Heidelberg University)Marc Müller(Medizinische Fakultät Mannheim)Rüdiger Hehlmann(University Hospital Heidelberg)Philipp Erben(Medizinische Fakultät Mannheim)Michael Lauseker(Ludwig-Maximilians-Universität München)Alice Fabarius(Medizinische Fakultät Mannheim)Susanne Schnittger(Munich Leukemia Laboratory (Germany))Claudia Haferlach(Munich Leukemia Laboratory (Germany))Gudrun Göhring(Medizinische Hochschule Hannover)Ulrike Proetel(Medizinische Fakultät Mannheim)H-J Kolb(LMU Klinikum)Stefan W. Krause(Universitätsklinikum Erlangen)W.‐K. Hofmann(Medizinische Fakultät Mannheim)Jörg Schubert(Evangelisches Krankenhaus Hamm)Hermann Einsele(Universitätsklinikum Würzburg)Jolanta Dengler(University Hospital Heidelberg)Mathias Hänel(Klinikum Chemnitz)Christiane Falge(Nuremberg Hospital)Lothar Kanz(Universitätsklinikum Tübingen)Andreas NeubauerMichael Kneba(University Hospital Schleswig-Holstein)Frank Stegelmann(University Hospital Ulm)Michael Pfreundschuh(Universitätsklinikum des Saarlandes)Cornelius F. Waller(University Medical Center Freiburg)Susan Branford(South Australia Pathology)Timothy P. Hughes(South Australia Pathology)Karsten Spiekermann(LMU Klinikum)Gabriela M. BaerlocherMarkus Pfirrmann(Zimmer Biomet (Germany))Joerg Hasford(Ludwig-Maximilians-Universität München)Susanne Saußele(Heidelberg University)Andreas Hochhaus(Jena University Hospital)for the SAKK and the German CML Study Group

View via DOI Publisher page

Chronic Myeloid Leukemia Treatments Eosinophilic Disorders and Syndromes Lymphoma Diagnosis and TreatmentImatinibInternal medicineMedicinePhiladelphia chromosomeMyeloid leukemiaImatinib mesylateOverall survivalCytogeneticsGastroenterologyOncology

MeSH terms

Imatinib MesylateAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBenzamidesCytarabineFemaleHumansInterferonsMaleMiddle AgedPiperazinesPrognosis

Citations

416

FWCI

34.38

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Blood · 2013 · 1,979 citations

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Leukemia · 2016 · 845 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.